Russell Investments Group Ltd. Buys 14,631 Shares of BioLife Solutions, Inc. $BLFS

Key Points

• Russell Investments Group Ltd. increased its stake in BioLife Solutions by 5.4% during Q1, owning 286,893 shares valued at approximately $6.55 million.
• BioLife Solutions reported a quarterly loss of ($0.33) earnings per share, missing the consensus estimate by ($0.31), despite a revenue of $25.42 million.
• Major shareholder Casdin Partners Master Fund, L sold 1,000,000 shares for $23.80 each, reducing their position by 11.48% to maintain ownership of 7,707,165 shares.

Russell Investments Group Ltd. raised its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 5.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 286,893 shares of the medical equipment provider's stock after purchasing an additional 14,631 shares during the period. Russell Investments Group Ltd. owned 0.60% of BioLife Solutions worth $6,553,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of BLFS. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of BioLife Solutions in the fourth quarter worth $31,000. US Bancorp DE boosted its position in shares of BioLife Solutions by 243.7% in the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider's stock valued at $49,000 after acquiring an additional 1,528 shares during the period. GAMMA Investing LLC boosted its position in shares of BioLife Solutions by 18.6% in the first quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock valued at $96,000 after acquiring an additional 663 shares during the period. Avantax Advisory Services Inc. grew its stake in BioLife Solutions by 16.0% during the first quarter. Avantax Advisory Services Inc. now owns 9,077 shares of the medical equipment provider's stock valued at $207,000 after acquiring an additional 1,250 shares in the last quarter. Finally, Graham Capital Management L.P. purchased a new stake in BioLife Solutions in the 4th quarter worth approximately $254,000. 93.24% of the stock is owned by institutional investors.

Insider Activity at BioLife Solutions

In related news, major shareholder Casdin Partners Master Fund, L sold 1,000,000 shares of BioLife Solutions stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $23.80, for a total value of $23,800,000.00. Following the transaction, the insider owned 7,707,165 shares in the company, valued at $183,430,527. This trade represents a 11.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders have sold 2,008,831 shares of company stock worth $47,499,658. 2.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms have recently commented on BLFS. Zacks Research upgraded shares of BioLife Solutions to a "strong-buy" rating in a research report on Monday, August 11th. Stephens initiated coverage on BioLife Solutions in a research note on Tuesday, July 22nd. They issued an "overweight" rating and a $30.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $32.00 price target (up previously from $30.00) on shares of BioLife Solutions in a report on Friday, August 8th. Finally, Wall Street Zen downgraded BioLife Solutions from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. One investment analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. Based on data from MarketBeat, BioLife Solutions currently has a consensus rating of "Buy" and a consensus target price of $31.29.

BioLife Solutions Stock Performance

NASDAQ:BLFS traded up $0.83 during mid-day trading on Friday, reaching $25.91. The stock had a trading volume of 652,188 shares, compared to its average volume of 557,506. The stock has a market capitalization of $1.24 billion, a P/E ratio of -215.90 and a beta of 1.76. The firm has a 50 day moving average price of $22.32 and a two-hundred day moving average price of $23.39. BioLife Solutions, Inc. has a one year low of $19.10 and a one year high of $29.55.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.31). The business had revenue of $25.42 million for the quarter, compared to the consensus estimate of $23.71 million. BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. BioLife Solutions has set its FY 2025 guidance at EPS. Research analysts forecast that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.